Response and resistance mechanisms of therapeutics targeting kinase signaling pathways in solid tumors utilizing prostate cancers as model systems. Molecular biology of hormone refractory prostate cancer progression with a focus on discovery and development of novel therapeutics.
Discovery of EMP-1 as a biomarker of gefitinib resistance. Novel cross-talk mechanisms between EGFR and PPARg signaling networks.
Role of Epithelial to mesenchymal transitions in targeted therapy response. Monitoring therapeutic response with phosphoproteomics based signatures. Androgen receptor signaling.
© Copyright 2000-2007 Cedars-Sinai Health System. All rights reserved.
Terms and Conditions